Sign up to receive information through Hypertension Care, including educational materials and other resources for your patients.

Register Here Register Here

Proven Power in Moderate Patients in the Matrix Trial

In the pivotal MATRIX Trial, which studied patients with moderate hypertension, a mean systolic blood pressure (SBP) reductions of 27 mm Hg and 16 mm Hg were seen in the BENICAR HCT 40/25 mg and BENICAR 40 mg treatment arms, respectively.1

Please see Important Safety Information, including Boxed Warning regarding Fetal Toxicity on this page.

Learn More Hero

In addition to offering proven medications
to help pull down patients’ BP, Daiichi
Sankyo offers valuable programs and
educational support for patients.

Find Out More Hypertension Care Toolbox

Daiichi Sankyo is committed to helping your patients work toward their BP goal

Savings That Last Program

The Savings That Last card rewards patient compliance by lowering co-pays over time. Also, as an added benefit, Daiichi Sankyo will pay for up to 3 add-on generic antihypertensives if a patient does not reach BP goal while on an olmesartan-based product.

Find Out More Hero

Clinical Study

MATRIX Trial: In an 8-week, randomized, double-blind, placebo-controlled trial, BENICAR HCT 40/25 mg reduced mean BP by 27/22 mm Hg and BENICAR 40 mg reduced mean BP by 16/14 mm Hg from baseline to Week 8. Placebo reduced BP by 3/8 mm Hg. Mean baseline BP was 154/103 mm Hg. Most common adverse reactions in this study (>2%) were dizziness, upper respiratory tract infection, nausea, and hyperuricemia. For more information, please see the MATRIX Trial within the website.

Hypertension Care provides products and services for patients taking olmesartan-based products: Savings That Last co-pay cards can help eligible patients save on prescriptions (terms of use and exclusions apply); the Hypertension Reimbursement Hotline provides reimbursement support to patients; product samples to help find the right drug and dosage for patients before they pay for an entire prescription; and the Right Fit Blood Pressure Program provides patients with disease management information.

Register Now with BENICAR

Sign up to receive information through Hypertension Care, including educational
materials and other resources for your patients.

For patients with commercial insurance, savings per prescription of BENICAR®, BENICAR HCT®, AZOR®, or TRIBENZOR® will apply after the following out-of-pocket expenses are met: $25 per prescription from months 1 to 6; $20 per prescription from months 7 to 12; and $15 per prescription after month 12. Savings begin after card activation and first fill. One month is defined as a 30-tablet supply being filled; 3 months is defined as one 90-day tablet supply being filled through retail or mail order. Savings for BENICAR, BENICAR HCT, AZOR, and TRIBENZOR are subject to a maximum benefit of $70 per 30-day prescription and $125 per 90-day prescription. Savings benefit does not cover a patient's insurance deductible obligation. Patients without insurance receive $25 off retail price. Up to 3 generic blood pressure medications offer applies only to patients with commercial insurance. Maximum benefit for each generic is $25 per prescription. You must fill your BENICAR, BENICAR HCT, AZOR or TRIBENZOR prescription and have a valid prescription for each generic blood pressure medication paid for by Daiichi Sankyo under the Medication offer. You must present this card to the pharmacist along with your BENICAR, BENICAR HCT, AZOR or TRIBENZOR prescription to participate in this program. It is illegal to (or offer to) sell, purchase, or trade these offers. Card will be inactivated if 120 days have passed since your last use. When you use this card you are certifying that you understand the program rules, regulations, and terms and conditions. If your retail or mail-order pharmacy does not accept the Savings That Last card, please call 1-855-809-5826 (8 am -8 pm ET, M -F) or visit to obtain a patient rebate form and to receive instructions on how to obtain your savings benefit. You are not eligible if you are enrolled in any state or federal healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE/CHAMPUS; where taxed, restricted, or prohibited by law; or if you do not otherwise comply with the terms herein. Further, you agree to discontinue using the card if you enroll in a state or federal healthcare program during the program period. Card void in Massachusetts and Michigan. Offers valid in U.S. and Puerto Rico only. If you have questions regarding your eligibility or benefits, or wish to discontinue participation, call the Savings That Last program at 1-855-809-5826 (8 am -8 pm ET, M -F). Daiichi Sankyo, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.


BENICAR, AZOR, and TRIBENZOR are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which these drugs principally belong. There are no controlled trials demonstrating risk reduction with BENICAR, AZOR, or TRIBENZOR.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

BENICAR HCT is indicated for the treatment of hypertension. BENICAR HCT is not indicated for initial therapy.

BENICAR, BENICAR HCT, AZOR, and TRIBENZOR can be used alone or with other antihypertensive agents.

AZOR is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.

Initial therapy with AZOR is not recommended in patients ≥75 years of age or in hepatically impaired patients.

TRIBENZOR is not indicated for the initial therapy of hypertension.

Important Safety Information



  • When pregnancy is detected, discontinue BENICAR, BENICAR HCT, AZOR, or TRIBENZOR as soon as possible
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS AND PRECAUTIONS: Fetal Toxicity

Do not co-administer aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with diabetes.

BENICAR HCT and TRIBENZOR are contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.


Morbidity in Infants: Children <1 year of age must not receive BENICAR for hypertension.

Fetal Toxicity: BENICAR, BENICAR HCT, AZOR, and TRIBENZOR are Pregnancy Category D.

Hypotension in Volume- or Salt-Depleted Patients: In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.

Impaired Renal Function: Monitor for worsening renal function in patients with renal impairment while on BENICAR,

In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (eg, patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Similar results may be anticipated in patients treated with BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported and similar results may be expected with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.

BENICAR HCT is not recommended in patients with severe renal impairment. Avoid use of TRIBENZOR in patients with severely impaired renal function (creatinine clearance ≤30 mL/min). If progressive renal impairment becomes evident, consider withholding or discontinuing TRIBENZOR.

Sprue-like Enteropathy: Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Consider discontinuation of BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in cases where no other etiology is identified.

Hepatic Impairment: Initial therapy with AZOR or TRIBENZOR is not recommended in hepatically impaired patients. In patients with severe hepatic impairment, exercise caution with AZOR and avoid use of TRIBENZOR. Thiazides (a component in
BENICAR HCT and TRIBENZOR) should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Electrolyte and Metabolic Imbalances: Due to the hydrochlorothiazide (HCTZ) component in BENICAR HCT and TRIBENZOR, observe patients for clinical signs of metabolic, fluid, or electrolyte imbalance.

Hypersensitivity Reaction: Hypersensitivity reactions to HCTZ (a component in BENICAR HCT and TRIBENZOR) may occur in patients with or without a history of allergy or bronchial asthma.

Systemic Lupus Erythematosus: Thiazides (a component in BENICAR HCT and TRIBENZOR) have been reported to cause exacerbation or activation of systemic lupus erythematosus.

Acute Myopia and Secondary Angle-Closure Glaucoma: Thiazides can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Discontinue HCTZ (a component in BENICAR HCT and TRIBENZOR) as rapidly as possible in these patients.

Vasodilation: Although vasodilation attributable to amlodipine (a component in AZOR and TRIBENZOR) is gradual in onset, acute hypotension has rarely been reported after oral administration. Patients with severe aortic stenosis may be at particular risk.

Increased Angina and/or Myocardial Infarction: Patients taking AZOR or TRIBENZOR, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dose increase.

Laboratory Tests: There was a greater decrease in hemoglobin and hematocrit with AZOR compared to either component alone. Other lab abnormalities may include increased blood creatinine levels and hyperkalemia (olmesartan medoxomil), hepatic enzyme elevations (amlodipine), and increased cholesterol and triglyceride levels (HCTZ).


Non-Steroidal Anti-Inflammatory Agents: Concurrent administration of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to increased risk of renal impairment (including possible acute renal failure) and loss of antihypertensive effect of BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.

Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on BENICAR, BENICAR HCT, AZOR, or TRIBENZOR and other agents that affect the RAS.

Avoid use of aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with renal impairment (GFR <60 mL/min).

Concurrent Use with Colesevelam Hydrochloride: Concurrent administration of colesevelam hydrochloride with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR reduces the systemic exposure and peak plasma concentration of olmesartan. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose.

Effect of Amlodipine on Simvastatin: Due to increased exposure to simvastatin, when co-administered with amlodipine (a component in AZOR and TRIBENZOR), do not exceed doses of greater than 20 mg daily of simvastatin.

Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of olmesartan or thiazide diuretics. Monitor lithium levels in patients receiving BENICAR, BENICAR HCT, AZOR, or TRIBENZOR and lithium.


BENICAR: The only adverse reaction that occurred in >1% of patients treated with BENICAR and more frequently than placebo was dizziness (3% vs 1%).

BENICAR HCT: Adverse reactions reported in >2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%).

AZOR: The only adverse reaction that occurred in ≥3% of patients treated with AZOR and more frequently than placebo was edema.

TRIBENZOR: The most frequently reported adverse reaction was dizziness (5.8% to 8.9%). The other most frequent adverse reactions occurring in ≥2% of patients treated with TRIBENZOR were peripheral edema (7.7%), headache (6.4%), fatigue (4.2%), nasopharyngitis (3.5%), muscle spasms (3.1%), nausea (3.0%), upper respiratory tract infection (2.8%), diarrhea (2.6%), urinary tract infection (2.4%), and joint swelling (2.1%).


Nursing Mothers: Avoid use while nursing; discontinue either nursing or the drug.


Please see Full Prescribing Information for BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.

  1. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-195.
  2. Weir MR, Punzi HA, Flack JM, et al. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with Stage 1 and 2 hypertension. Postgrad Med. 2011;123:80-87.
  3. Data on file. Daiichi Sankyo, Inc., Parsippany, NJ.

Email This Page

After completing the fields below and clicking "SUBMIT," your colleague will receive an email with a link to this page.

* Required information

* Your First Name

* Your Last Name

* Your Email Address

* Recipient's Email Address

You are leaving

Please note: You are about to leave the website and go to the  website.